Clinical Trial Update: Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant aumolertinib in AI-diagnosed EGFR-mutant high-risk pulmonary ground-glass opacity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN